DNTH — Dianthus Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
$106.63
+$0.01 (+0.01%)
Dianthus Therapeutics Inc. (DNTH) is a biotechnology company listed on NASDAQ. It is led by Marino Garcia M.B.A., based in 7 Times Square, New York, NY, United States, 10036, with about 92 employees. Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Latest reported DNTH revenue for 2025-09-30 was $396.0K. Net income was -$97.9M. Revenue was up 105.2% from 2025-06-30 to 2025-09-30. DNTH currently screens at market cap $4.40B.
Use this DNTH page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the DNTH quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the DNTH SEC filings page. Lician reads the product cache first so this HTML stays unique to Dianthus Therapeutics Inc. even when a live quote feed is slow.
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
DNTH Key Statistics
Market Cap
$4.40B
Volume
224,775
Previous Close
$110.07
Day Range
$110.35 – $113.86
EPS
-$2.55
Revenue
$6.24M
Net Income
-$84.97M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+120.6%
Profit Margin
-1362.8%
Employees
92
DNTH Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $6.24M | $2.83M | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$84.97M | -$43.55M | -$28.48M |
| EPS (Diluted) | -$2.55 | -$8.45 | -$32.57 |
Total Assets
$374.01M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$22.79M
Operating Cash Flow
-$78.18M
Free Cash Flow
$0.00
Dianthus Therapeutics Inc. Company Information
- President, CEO & Director
- Marino Garcia M.B.A.
- Headquarters
- 7 Times Square, New York, NY, United States, 10036
- Website
- dianthustx.com
- Phone
- 929 999 4055
- IPO / Founded
- 2023-09-12
- Sector
- Healthcare
- Industry
- Biotechnology